SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...
This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic ...
FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...
SurvivorNet on MSN
'Practice-changing': FDA approves Ibrance combination as new maintenance option for HR+/HER2+ metastatic breast cancer
The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...
Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...
Advanced HR-positive breast cancer management is evolving with personalized therapies, improving disease control and quality of life. First-line treatment combines anti-estrogen therapy with CDK 4/6 ...
Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. "We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results